Table 3 Anti-infective therapies of the four groups of patients with HAI.

From: Epidemiology, clinical relevance and prognosis of staphylococci in hospital-acquired postoperative intra-abdominal infections: an observational study in intensive care unit

Variables

nS-HAI

n = 293

S-HAI

n = 87

CoNS-HAI

n = 58

Sa-HAI

n = 29

Missing data

Empirical anti-infective therapy

Monotherapy

57 (19)

16 (18)

12 (21)

4 (14)

–

Vancomycin

129 (44)

40 (46)

25 (43)

15 (52)

–

Adequate EAT

211 (72)

47 (54)**

28 (48)

19 (66)

–

Documented anti-infective therapy

Monotherapy

109 (37)

24 (28)

17 (29)

7 (24)

–

Carbapenem

61 (21)

24 (28)

20 (34)

4 (14) †

–

Piperacillin/tazobactam

98 (33)

24 (28)

12 (21)

12 (41) †

–

Vancomycin

68 (23)

43 (49)**

31 (53)

12 (41)

–

Aminoglycosides

39 (13)

14 (16)

8 (14)

6 (21)

–

Duration (days)

10 [7–14]

10 [10–14]

10 [8–14]

10 [10–15]

1/0/0/0

De-escalation

175 (60)

43 (49)

23 (40)

20 (69)††

–

Escalation

48 (16)

31 (36)**

26 (45)

5 (17)†

–

  1. nS-HAI infection without staphylococci peritoneal cultures, S-HAI infection with positive staphylococci peritoneal culture, Sa-HAI infection with Staphylococcus aureus positive peritoneal culture, CoNS-HAI infection with coagulase-negative staphylococci peritoneal culture, EAT empirical anti-infective therapy, HAI hospital-acquired postoperative intra-abdominal infection, ICU intensive care unit.
  2. [25th–75th]: [25th–75th percentiles].
  3. °Results obtained in survivors.
  4. **p < 0.01 between the nS-HAI and S-HAI groups; †p < 0.05 and ††p < 0.01 between the CoNS-HAI and Sa-HAI groups.
Back to article page